Immediate Impact

1 from Science/Nature 53 standout
Sub-graph 1 of 23

Citing Papers

Advance in peptide-based drug development: delivery platforms, therapeutics and vaccines
2025 Standout
Subcutaneously administered tirzepatide vs semaglutide for adults with type 2 diabetes: a systematic review and network meta-analysis of randomised controlled trials
2024 Standout

Works of So Nagai being referenced

Improvement of glycaemic control and treatment satisfaction by switching from liraglutide or dulaglutide to subcutaneous semaglutide in patients with type 2 diabetes: A multicentre, prospective, randomized, open‐label, parallel‐group comparison study ( SWITCH‐SEMA 1 study)
2023
Glycaemic control efficacy of switching from dipeptidyl peptidase‐4 inhibitors to oral semaglutide in subjects with type 2 diabetes: A multicentre, prospective, randomized, open‐label, parallel‐group comparison study ( SWITCH‐SEMA 2 study)
2023

Author Peers

Author Last Decade Papers Cites
So Nagai 226 270 105 195 50 674
Katsuhiro Miyajima 230 260 133 185 69 781
Shinichiro Koike 146 210 96 305 20 663
S Kralisch 154 291 229 248 28 744
Hilda Vargas‐Robles 109 275 113 121 42 792
Ming Lu 192 349 127 163 36 813
R. Renner 272 242 34 157 41 718
Tetsu Ebara 353 229 81 111 28 792
Takatoshi Saito 121 437 51 170 28 817
Jean‐Pierre Clot 222 275 46 203 35 766
Munetada Oimomi 307 176 69 184 60 811

All Works

Loading papers...

Rankless by CCL
2026